The invention relates to a method for in vitro predicting the outcome of an individual having a multiple myeloma, comprising the steps of:-a) measuring the expression level of at least 5 genes and/or proteins encoded by the said 5 genes, the said genes being selected in a group comprising NRP2, REEP1, SV2B, ARRB1, CACNA1G, FBLIM1, FGFR1, IRF6, ITGA9, NOVA2, PPP2R2C, SLC5A1, SORL1, SYT7 and THY1, in a biological sample obtained from said individual；-b) calculating a score value from said expression level obtained at step a)；-c) classifying the said individual as having a good prognosis status or a bad prognosis status, by comparing the score value obtained at step b) with a reference score value.
